Trial reportJournal of addiction medicine2012
Comparison of buprenorphine treatment for opioid dependence in 3 settings.
Trial report in Journal of addiction medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Evaluating comparative effect of non-pharmacological interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analysis.Addiction (Abingdon, England) · 2026Pooled it
- Opioid agonist therapy for opioid use disorder in primary versus specialty care.The Cochrane database of systematic reviews · 2025Pooled it
- Pooled it
- Retention in medication-assisted treatment for opiate dependence: A systematic review.Journal of addictive diseases · 2016Pooled it
- Adapting psychotherapy in collaborative care for treating opioid use disorder and co-occurring psychiatric conditions in primary care.Families, systems & health : the journal of collaborative family healthcare · 2023Trial
- Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months.The American journal of drug and alcohol abuse · 2018Trial
- A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.Drug and alcohol dependence · 2014Trial
- Retention in methadone and buprenorphine treatment among African Americans.Journal of substance abuse treatment · 2013Trial
- Retention Challenges in Opioid Use Disorder Treatment: The Role of Comorbid Psychological Conditions.The western journal of emergency medicine · 2025Article
- How to Combat the Global Opioid Crisis.CPQ neurology and psychology · 2023Article
- Differences in buprenorphine treatment quality across physician provider specialties.Drug and alcohol dependence · 2022Article
- A mixed methods study of provider factors in buprenorphine treatment retention.The International journal on drug policy · 2022Article
- Three-month outcomes from a patient-centered program to treat opioid use disorder in Iowa, USA.Substance abuse treatment, prevention, and policy · 2021Observational
- New Approaches in Drug Dependence: Opioids.Current addiction reports · 2021Review
- Buprenorphine Treatment for Opioid Use Disorder in Community-Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results.The American journal on addictions · 2020Article
- A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment.Contemporary clinical trials · 2019Article
- Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States.Pharmacoepidemiology and drug safety · 2019Article
- The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.The American journal of psychiatry · 2017Review
- Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?Canadian family physician Medecin de famille canadien · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
unlabelledAlthough use of buprenorphine in the treatment of opioid dependence is expected to continue to increase, little is known about the optimal setting for providing the medical and psychosocial care required with buprenorphine pharmacotherapy.
objectiveThis study compared buprenorphine therapy delivered in 3 distinct treatment settings: an opioid treatment program (OTP) offering individual counseling, a group counseling program utilizing the manualized Matrix Model (MMM) of cognitive-behavioral treatment, and a private clinic setting mirroring standard medical management for buprenorphine treatment provided specifically at a psychiatrist's private practice (primary care setting).
methodParticipants were inducted on buprenorphine and provided with treatment over a 52-week study duration. All participants were scheduled for weekly treatment visits for the first 6 study weeks and 2 sites reduced treatment to monthly visits for dispensing of medication and psychosocial counseling. Outcomes include opioid use, participant retention in treatment, and treatment participation.
resultsParticipants presenting for treatment at the sites differed only by race/ethnicity and opioid use did not differ by site. Retention differed by treatment site, with the number of participants who stayed in the study until the end of 20 weeks significantly associated with treatment site. The mean number of minutes spent in each individual counseling session also differed by site. Although no difference in opioid use by treatment site was found, results document a significant association between opioid use and buprenorphine dose. DISCUSSION: These results show some differences by treatment site, although the similarity and relative ease in which the sites were able to recruit participants for treatment with buprenorphine, and minor implementation problems reported suggests the feasibility of treatment with buprenorphine across various treatment settings.
conclusionSimilar rates of continued opioid use across study sites and few qualitative reports of problems indicates that treatment with buprenorphine and associated psychosocial counseling are safe and relatively easy to implement in a variety of treatment settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.